Waters Acquires MOBILion to Strengthen Mass Spectrometry Platform and Proteomics Research
Key Facts
Waters announced on November 3, 2026, that it had acquired MOBILion Systems, developer of SLIM high-resolution ion mobility separation technology, in a move aimed at expanding its capabilities in proteomics research. The deal combines the new separation technology with Waters’ mass spectrometry platform, adding a molecular separation stage to tools for analyzing complex biological samples. Chief Executive Officer Udit Batra said the acquisition gives the company “a unique advantage in proteomics that reinforces our leadership, first in research and then, over time, in clinical applications.” Waters did not disclose the financial terms of the deal. The company described clinical applications as a potential long-term pathway, not an outcome already achieved.
SLIM separates molecules by size, shape and charge in fractions of a millisecond, according to Waters’ description. The company plans to combine it with the speed and accuracy of the Xevo MRT MS instrument, expanding analysis of complex proteins compared with relying on liquid chromatography and mass spectrometry alone. Waters said the technology is expected to increase proteome coverage, measurement sensitivity and throughput for complex biological samples. In the company’s view, the integration adds a way to separate molecules before analyzing them within its existing mass spectrometry system. The deal therefore focuses on advancing research and analytical tools, while subsequent medical applications remain contingent on clinical validation.
Waters estimates the total addressable market for liquid chromatography mass spectrometry-based proteomics at about $2 billion, and says it is growing at a high-single-digit annual rate. The company also links the platform to AI-enabled proteomics research, which relies on generating large-scale data and laboratory experiments. According to its description, AI agents could help design experiments and direct instruments to operate autonomously. Waters places these capabilities within an effort to integrate laboratory measurement and data flows in the search for biomarkers. The market-size and growth-rate estimates remain the company’s estimates as stated in its acquisition announcement.
Waters describes a pathway that starts with biomarker discovery, followed by validation and adoption in clinical trial cohorts, on a single platform. The company also sees a future opportunity to expand menus of multiplex diagnostic tests, drawing on its installed base of mass spectrometry instruments in clinical laboratories. The applications it cited include blood tests for early cancer detection and monitoring residual disease. Waters said the deal “enables a pathway from biomarker discovery to targeted validation and adoption in clinical trial cohorts.” These uses remain future opportunities, as the deal announcement did not report clinical approval or the launch of new tests.
The announcement came alongside third-quarter results that showed reported revenue of $1.767 billion, including $871 million in organic revenue and $896 million from acquired life sciences and diagnostics businesses. Organic revenue rose from $800 million in the third quarter of 2025, an increase of 9% on a reported basis and 10% in constant currency. Adjusted earnings per share also grew 21% to $4.10, compared with $3.40 a year earlier. The company said sales growth for liquid chromatography-mass spectrometry instruments accelerated to double digits in constant currency. It attributed this to instrument replacement trends and demand related to GLP-1 drugs, PFAS and generic products in India.
Waters shares closed at $457.6 on November 6, 2026, according to EL7 data. The close came three days after the acquisition announcement, and the available data do not include the stock’s trading range during the November 6 session. For the fourth quarter of 2026, the company forecast organic revenue growth of between 7% and 9% in constant currency. It also forecast adjusted earnings per share of between $4.58 and $4.68. The next-quarter forecasts are separate from the research and clinical prospects the company linked to integrating MOBILion technology.